SOHO 2023 Eleventh Annual Meeting

 

SOHO 2023 Eleventh Annual Meeting
T

SOHO 2023: How Biologic Markers Impact CLL Outcomes With Novel Therapy

By SOHO 2023 Eleventh Annual Meeting FEATURING Talha Munir
By SOHO 2023 Eleventh Annual Meeting FEATURING Talha Munir
54 views
October 18, 2023
0 Comments
Login to view comments. Click here to Login

Featured Video

24:08
Indy Hematology Review

Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Feat. A. Tefferi

Featured Video

24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray
Leukemia
37:10
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: CML and Pregnancy

Feat. E. Abruzzese
11:02
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Next Questions: AML

Feat. F. Ravandi
57:31
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: ‘Level Up’ With Personalized Care for CLL/SLL - Achieving…

Feat. W. Wierda, N. Lamanna, M. Thompson
10:22
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Next Questions: CLL

Feat. N. Jain
10:37
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Next Questions: CML

Feat. P. Rousselot
10:16
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Next Questions: ALL

Feat. E. Jabbour
13:18
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: What Is New in the WHO Classification of AML?

Feat. S. Loghavi
15:12
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: What Is New in the ICC Classification of AML?

Feat. R. Hasserjian
10:22
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: How Do We Reconcile These AML Classifications in Clinical…

Feat. A. Wei
16:55
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Post-Transplant Maintenance Therapy for Patients With AML:…

Feat. B. Oran
15:27
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 DEBATE: Prior Therapy Not Needed for Transplanting Patient…

Feat. J. Schetelig
12:17
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 DEBATE: Achieving Best Response Is Desirable Prior to Allo…

Feat. R. Walter
16:11
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Familial Predisposition to AML: Prevalence & Implicati…

Feat. L. Godley
08:22
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Impact of Consolidation Chemo Intensity Before Allogeneic…

Feat. Y. Hicheri
15:01
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 DEBATE: Patients With AML and Active Disease Should Be Tra…

Feat. H. Fernandez
13:59
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 DEBATE: Against Allogeneic Transplantation for AML Patient…

Feat. E. Waller
12:48
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Genomic Complexity Beyond BCR::ABL1 and Its Clinical Impa…

Feat. D. Ross
13:31
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Epigenetic Dysregulation of CML

Feat. T. Ong
16:25
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: The New ELN Laboratory Recommendations for the Diagnosis …

Feat. N. Cross
07:50
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Phase II PACE Trial 5-Year Data: Early Cytogenetic or Mole…

Feat. H. Kantarjian
15:49
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: How Biologic Markers Impact CLL Outcomes With Novel Thera…

Feat. T. Munir
16:22
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Clinical Significance of MBL

Feat. S. Parikh
15:57
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: What Is the Future of Menin Inhibitors in AML?

Feat. G. Issa
15:40
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: CNS Prophylaxis in ALL

Feat. P. Kebriaei
09:01
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Sequencing Immunotherapies in Adults With B-ALL

Feat. B. Shah
15:23
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Updates on the Role of SCT in ALL in the Era of CAR-T

Feat. J. Park
07:04
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Comparison of Treatment Outcomes in Adolescents and Young…

Feat. O. Shahin
08:21
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Results from the QuANTUM-First Trial: Impact of allo-HCT i…

Feat. A. Perl
13:39
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Triplet Regimens in AML: Beyond Azacitidine + Venetoclax

Feat. C. DiNardo
23:11
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Navigating the Treatment Value of TKIs in CML in the Era …

Feat. H. Kantarjian
08:35
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Primary Analysis of the Phase 1/2, Single-Arm, Multicenter…

Feat. T. Siddiqi
17:30
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Rational TKI Choice in CML

Feat. M. Deininger
17:27
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: How We Developed a Curative Therapy for CLL and Stopped U…

Feat. J. Seymour
16:04
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Is Finite Duration Therapy the New Standard of Treatment …

Feat. A. Ferrajoli
26:59
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Debate: MRD+ After 1 Year of VenG in CLL - Stop or Continu…

Feat. O. Al-Sawaf, N. Lamanna
19:15
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: CML - Are We Doing It Right?

Feat. J. Cortés
20:29
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Slow-Motion Therapeutic Revolution in Adult ALL

Feat. H. Kantarjian
15:34
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Is AML With Monocytic Features a Separate Entity?

Feat. D. Pollyea
18:13
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: What Is the Role of Quizartinib in the Current Landscape …

Feat. H. Erba
08:22
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 First Report of Phase 3 PhALLCON Study: Comparing Ponatini…

Feat. E. Jabbour
17:45
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Acute Leukemia of Ambiguous Lineage

Feat. C. Saygin
15:25
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Management of Newly Diagnosed Ph+ ALL: Novel Drugs and Str…

Feat. E. Jabbour
13:15
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Menin Inhibition for KMT2A-Rearranged ALL

Feat. E. Stein
15:42
SOHO 2023 Eleventh Annual Meeting

SOHO 2023 Approach to Ph-Like ALL

Feat. I. Iacobucci